Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034Martin J. van den Bent, Thierry Gorlia, Johan M. Kros et al.|Journal of Clinical Oncology|2009Cited by 573
CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDYBrigitta G. Baumert, Roger Stupp, Monika E. Hegi et al.|Neuro-Oncology|2024Cited by 4